The only adult RSV protection available in a pre-filled syringe1-3
Ready to protect against RSV. No reconstitution required.1 mRESVIA is a single-dose 0.5 mL pre-filled syringe, ready for you to use for protection against RSV.1
Pre-filled syringes offer a convenient way to administer protection.1,4,5
mRESVIA Box Dimensions: 55 x 87 x 133mm
Storage and handling options1
Your mRESVIA pre-filled syringes can be stored in a freezer, refrigerator, or at room temperature, with varying storage times.1*
Store in the freezer
-40°F to 5°F (-40°C to -15°C)1
Store up to 30 days† in the refrigerator
36°F to 46°F (2°C to 8°C)1
Thaw duration in refrigerator 60 minutes (pre-filled syringe in single blister pack)1 or 155 minutes (carton of 10)1
Store up to 24 hours‡ at room temperature
46°F to 77°F (8°C to 25°C)1
Thaw duration at 59°F to 77°F (15°C to 25°C) 45 minutes (pre-filled syringe in single blister pack)1 or 140 minutes (carton of 10)1
Storage and administration considerations
- Do not shake mRESVIA1
- Avoid exposure to direct sunlight and/or ultraviolet light, and minimize exposure to room light1
- Do not refreeze after thawing or refrigerate after storing at room temperature1
Check out the mRESVIA Product Information Quick Guide
Download now*If thawed in the refrigerator, syringes should be left at room temperature for an additional 10 to 20 minutes before administration. Discard any syringes left at room temperature for over 24 hours.1
†Following frozen storage.1
‡Following refrigerated storage.1
RSV = respiratory syncytial virus.
Indication
mRESVIA® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
Important Safety Information
Contraindications
Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.
Warnings and Precautions
- Management of Acute Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
- Syncope: Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
- Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.
Adverse Reactions
In a clinical trial, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).
To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
Please click for mRESVIA Full Prescribing Information.
References
- mRESVIA Prescribing Information. ModernaTX, Inc.
- AREXVY Prescribing Information. GlaxoSmithKline Biologics SA.
- ABRYSVO Product Information. Pfizer Inc.
- Icardi G, Orsi A, Vitali Rosati G, Tognetto A, Checcucci Lisi G, Parisi S. Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations. J Prev Med Hyg. 2020;61(3):E424-E444. doi:10.15167/2421-4248/jpmh2020.61.3.1535
- Yarnoff B, Bodhaine S, Cohen E, Buck PO. Time and cost of administering COVID-19 mRNA vaccines in the United States. Hum Vaccin Immunother. 2021;17(11):3871-3875. doi:10.1080/21645515.2021.1974289
For Colorado and Connecticut price disclosure, please visit https://modernadirect.com/wac-disclosure
Stay up to date
Receive the latest information about mRESVIA and all the products in the Moderna pipeline.
By submitting your information, you agree to Moderna's Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna's Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© 2024 Moderna US-RSV-2400107 09/2024